Vivera Pharmaceuticals

Executive Summary

Vivera Pharmaceuticals is a science-driven biopharma and medtech company based in Southern California, specializing in innovative drug delivery technologies. The company holds global exclusivity to license the patented TABMELT sublingual drug delivery system for pharmaceutical use, offering rapid absorption and improved bioavailability. Additionally, Vivera owns issued patents on ZICOH, an intelligent dose-controlled electronic prescription dispensing device, and MDZone, a portable telemedicine station. With multiple divisions, the company aims to bridge the gap between pharmaceutical development and patient-centric care, enhancing medication adherence and telemedicine accessibility. Despite being a private entity with limited public financial disclosures, Vivera's proprietary platforms position it as a potential disruptor in drug delivery and connected health. The company's focus on sublingual delivery and smart dispensing aligns with industry trends toward convenience and precision medicine. Key near-term milestones include potential regulatory clearances and commercial partnerships that could validate its technology and drive revenue growth.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance or 510(k) for ZICOH smart dispenser60% success
• Q4 2026Licensing deal for TABMELT with a major pharma partner40% success
• 2027Deployment of MDZone telemedicine stations in healthcare systems50% success